Latest Orexigen Therapeutics (OREX) Headlines
Could Orexigen Therapeutics Be Another Arena or VIVUS?
George Budwell, The Motley Fool - Motley Fool - 1 hr 54 mins ago
I'll never forget watching Arena Pharmaceuticals and VIVUS in early 2012 as each company headed into their regulatory reviews with the U.S. Food and Drug Administration, or FDA, for their respective obesity medications. It was certainly a sight...
Narrower Loss at Orexigen in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 38 mins ago
Orexigen Therapeutics reported a net loss of 21 cents per share in the fourth quarter of 2013.
Orexigen Therapeutics Reduces Q4 Loss by 34%
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 12, 4:27PM CDT
Fat-fighting clinical-stage biopharmaceutical company Orexigen Therapeutics posted a narrower fourth-quarter loss on the back of lower research and development expenses. For the quarter, Orexigen recorded $857,000 in revenue which is...
Orexigen Therapeutics Reports Corporate and Financial Results for the Fourth Quarter and Year Ended December 31, 2013
PR Newswire - Wed Mar 12, 3:01PM CDT
Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced corporate and financial results for the fourth quarter and year ended December 31, 2013.
'Mad Money' Lightning Round: Boston Scientific Is a Favorite
at The Street - Wed Mar 12, 5:00AM CDT
Cramer also loves Occidental Petroleum but he's not recommending Bed Bath & Beyond.
Jim Cramer's 'Mad Money' Recap: Silver Lining Playbook
at The Street - Tue Mar 11, 7:04PM CDT
The markets are a healthier place today, even though most investors lost money, Cramer says.
14.5% Return Seen to Date on SmarTrend Orexigen Therapeutics Call (OREX)
Comtex SmarTrend(R) - Wed Mar 05, 11:20AM CST
SmarTrend identified an Uptrend for Orexigen Therapeutics (NASDAQ:OREX) on January 10th, 2014 at $6.30. In approximately 2 months, Orexigen Therapeutics has returned 14.52% as of today's recent price of $7.22.
Have Anti-Obesity Drug Prospects Finally Gone Belly-Up?
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 04, 1:05PM CST
On paper, it just makes so much sense that physicians and patients would turn to chronic weight control management therapies offered by VIVUS and Arena Pharmaceuticals as in addition to proper diet and exercise to lose weight. But paper is...
Biotech Showdown: MannKind Corp. vs. Orexigen Therapeutics
George Budwell, The Motley Fool - Motley Fool - Tue Mar 04, 1:00PM CST
A drug approval for a developmental biotech can be a transformative event, especially when the drug in question has blockbuster potential. So, it's no wonder that risk-tolerant investors flock to drug stocks with pending New Drug Applications, or...
Orexigen Therapeutics to Host Full Year and Fourth Quarter 2013 Financial Results Conference Call and Webcast
PR Newswire - Mon Mar 03, 7:30AM CST
Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, will announce financial results for the full year and fourth quarter 2013, on Wednesday, March 12, 2014 after the markets close. The announcement will be followed by a live webcast and conference call at 5:00 p.m. Eastern time (2:00 p.m. Pacific time).
Orexigen Therapeutics to Present at the 34th Annual Cowen and Co. Health Care Conference
PR Newswire - Thu Feb 27, 7:30AM CST
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the 34th Annual Cowen and Co. Health Care Conference being held in Boston. The presentation is scheduled for Wednesday, March 5 at 9:20 a.m. Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.
Global Obesity Drug Forecast and Market Analysis to 2022 - Market to Reach $8.4 Billion
M2 - Thu Feb 27, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/l5mtst/pharmapoint) has announced the addition of the "PharmaPoint: Obesity - Global Drug Forecast and Market Analysis to 2022" report to their offering. Obesity Therapy Market to Reach $8.4 billion by 2022 Due to the launches of several novel drugs during the next decade, the obesity market will increase from $407m in 2012 to $8.4 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 35.3%, forecasts research and consulting firm The authors. The US, Canada and Japan will have the largest obesity therapy sales by 2022, with shares of $5.3 billion, $702m and $484m, respectively. The obesity space has seen little activity in the past decade due to a pharmacological history of modest efficacy, poor tolerability with dangerous side effects, and limited healthcare coverage, which have all contributed to the commercial failure of anti-obesity drugs. Recently, however, there has been a revival of this market space, as a couple of companies have released drugs that challenge these limitations. The two drugs that will have the greatest impact on the size of the market are Victoza and Belviq. Victoza's advantage, in addition to its efficacy, lies largely in the fact that it is marketed for the treatment of type 2 diabetes by Novo Nordisk. Belviq's advantage lies in its novelty; unlike Vivus' Qsymia and the two drugs being developed by Orexigen, it is a novel molecular entity, rather than a combination of existing therapeutic options. With the changing tide of opinion on the treatment of obesity and the upcoming launches of new drugs and devices, we anticipate that the prescribing of obesity therapies will increase over the next 10 years, boosting the market size, Wong says. Still, there is a lack of reimbursement for obesity drugs in the US and public health systems throughout the rest of the world, which could hinder any further market growth. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Agency for Medical Innovation - Allergan - Apollo Endosurgery - Arena Pharmaceuticals and Eisai - Aspire Bariatrics - Bariatric Solutions - Baronova - BaroSense - BFKW - C.R. Bard - Cousin Biotech - Endalis Laboratory - EndoGastric Solutions - EndoSphere - EnteroMedics - Ethicon Endo-Surgery - GI Dynamics - Helioscopie - IntraPace - Medical Innovation Development - MetaCure - Novo Nordisk - Obalon Therapeutics - Orexigen Therapeutics - ReShape Medical - Roche Holdings - Shionogi - Spatz Medical - Takeda Pharmaceutical Company - ValenTx For more information visit http://www.researchandmarkets.com/research/l5...harmapoint
Orexigen Therapeutics Shares Up 14.4% Since SmarTrend's Buy Recommendation (OREX)
Comtex SmarTrend(R) - Wed Feb 26, 9:59AM CST
SmarTrend identified an Uptrend for Orexigen Therapeutics (NASDAQ:OREX) on January 10th, 2014 at $6.30. In approximately 2 months, Orexigen Therapeutics has returned 14.44% as of today's recent price of $7.21.
Arena Pharmaceuticals, Inc. Earnings: What to Expect Thursday
Dan Caplinger, The Motley Fool - Motley Fool - Tue Feb 25, 11:01PM CST
Arena Pharmaceuticals will release its quarterly report on Thursday, and investors are more nervous than ever about the prospects for the maker of obesity drug Belviq. With rival VIVUS having reported another round of disappointing sales of its...
Why SINA, VIVUS, and Tenet Healthcare Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Tue Feb 25, 7:30PM CST
Stocks finished narrowly lower on Tuesday, as investors seemed content with the impressive gains they've scored so far this month after a terrible January. Yet even though broad market benchmarks fell only a fraction of a percent, much larger losses...
Another Big Failure for VIVUS, Inc.
David Williamson, The Motley Fool - Motley Fool - Tue Feb 25, 4:02PM CST
Vivus Pharmaceuticals is having an absolutely awful day, with the stock down more than 13% after the company reported its Q4 results. The launch of its first-in-class obesity drug Qsymia was very highly anticipated among investors with the market...
Why VIVUS Inc. Shares Slimmed Down
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 25, 11:58AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of VIVUS , a biopharmaceutical company...
Moving Average Crossover: Great News Orexigen Therapeutics (OREX)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 9:01AM CST
Moving Average Crossover: Great News Orexigen Therapeutics (OREX)?
Why VIVUS Inc. Is Falling Today
George Budwell, The Motley Fool - Motley Fool - Tue Feb 25, 8:33AM CST
VIVUS reported earnings after the bell yesterday and its shares have been on a roller coaster ride ever since. Immediately following the release, shares rose over 4%, but have now fallen close to 13% in premarket trading this morning. ...
Orexigen Provides Update on Its NB32 European Marketing Authorization Application
PR Newswire - Tue Feb 25, 7:00AM CST
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that the Company received the Day 120 List of Questions (LoQs) regarding its NB32 Marketing Authorization Application (MAA) from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP). The EMA reviewers' questions are consistent with issues raised by the United States Food and Drug Administration during the course of NB32 development and the initial review of the New Drug Application, such as manufacturing and quality, non-clinical studies, dosing regimen, and, most significantly, cardiovascular safety. The NB32 MAA is being reviewed by EMA regulators for the first time, and the LoQs represent the first formal interaction with the regulators since the MAA was filed in October. Orexigen is confident that it can successfully address all of the questions posed.
Could Orexigen Therapeutics Be Another Arena or VIVUS?
George Budwell, The Motley Fool - Motley Fool - 1 hr 54 mins ago
I'll never forget watching Arena Pharmaceuticals and VIVUS in early 2012 as each company headed into their regulatory reviews with the U.S. Food and Drug Administration, or FDA, for their respective obesity medications. It was certainly a sight...
Narrower Loss at Orexigen in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 38 mins ago
Orexigen Therapeutics reported a net loss of 21 cents per share in the fourth quarter of 2013.
Orexigen Therapeutics Reduces Q4 Loss by 34%
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 12, 4:27PM CDT
Fat-fighting clinical-stage biopharmaceutical company Orexigen Therapeutics posted a narrower fourth-quarter loss on the back of lower research and development expenses. For the quarter, Orexigen recorded $857,000 in revenue which is...
Orexigen Therapeutics Reports Corporate and Financial Results for the Fourth Quarter and Year Ended December 31, 2013
PR Newswire - Wed Mar 12, 3:01PM CDT
Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced corporate and financial results for the fourth quarter and year ended December 31, 2013.
'Mad Money' Lightning Round: Boston Scientific Is a Favorite
at The Street - Wed Mar 12, 5:00AM CDT
Cramer also loves Occidental Petroleum but he's not recommending Bed Bath & Beyond.
Jim Cramer's 'Mad Money' Recap: Silver Lining Playbook
at The Street - Tue Mar 11, 7:04PM CDT
The markets are a healthier place today, even though most investors lost money, Cramer says.
14.5% Return Seen to Date on SmarTrend Orexigen Therapeutics Call (OREX)
Comtex SmarTrend(R) - Wed Mar 05, 11:20AM CST
SmarTrend identified an Uptrend for Orexigen Therapeutics (NASDAQ:OREX) on January 10th, 2014 at $6.30. In approximately 2 months, Orexigen Therapeutics has returned 14.52% as of today's recent price of $7.22.
Have Anti-Obesity Drug Prospects Finally Gone Belly-Up?
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 04, 1:05PM CST
On paper, it just makes so much sense that physicians and patients would turn to chronic weight control management therapies offered by VIVUS and Arena Pharmaceuticals as in addition to proper diet and exercise to lose weight. But paper is...
Biotech Showdown: MannKind Corp. vs. Orexigen Therapeutics
George Budwell, The Motley Fool - Motley Fool - Tue Mar 04, 1:00PM CST
A drug approval for a developmental biotech can be a transformative event, especially when the drug in question has blockbuster potential. So, it's no wonder that risk-tolerant investors flock to drug stocks with pending New Drug Applications, or...
Orexigen Therapeutics to Host Full Year and Fourth Quarter 2013 Financial Results Conference Call and Webcast
PR Newswire - Mon Mar 03, 7:30AM CST
Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, will announce financial results for the full year and fourth quarter 2013, on Wednesday, March 12, 2014 after the markets close. The announcement will be followed by a live webcast and conference call at 5:00 p.m. Eastern time (2:00 p.m. Pacific time).
Orexigen Therapeutics to Present at the 34th Annual Cowen and Co. Health Care Conference
PR Newswire - Thu Feb 27, 7:30AM CST
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the 34th Annual Cowen and Co. Health Care Conference being held in Boston. The presentation is scheduled for Wednesday, March 5 at 9:20 a.m. Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.
Global Obesity Drug Forecast and Market Analysis to 2022 - Market to Reach $8.4 Billion
M2 - Thu Feb 27, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/l5mtst/pharmapoint) has announced the addition of the "PharmaPoint: Obesity - Global Drug Forecast and Market Analysis to 2022" report to their offering. Obesity Therapy Market to Reach $8.4 billion by 2022 Due to the launches of several novel drugs during the next decade, the obesity market will increase from $407m in 2012 to $8.4 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 35.3%, forecasts research and consulting firm The authors. The US, Canada and Japan will have the largest obesity therapy sales by 2022, with shares of $5.3 billion, $702m and $484m, respectively. The obesity space has seen little activity in the past decade due to a pharmacological history of modest efficacy, poor tolerability with dangerous side effects, and limited healthcare coverage, which have all contributed to the commercial failure of anti-obesity drugs. Recently, however, there has been a revival of this market space, as a couple of companies have released drugs that challenge these limitations. The two drugs that will have the greatest impact on the size of the market are Victoza and Belviq. Victoza's advantage, in addition to its efficacy, lies largely in the fact that it is marketed for the treatment of type 2 diabetes by Novo Nordisk. Belviq's advantage lies in its novelty; unlike Vivus' Qsymia and the two drugs being developed by Orexigen, it is a novel molecular entity, rather than a combination of existing therapeutic options. With the changing tide of opinion on the treatment of obesity and the upcoming launches of new drugs and devices, we anticipate that the prescribing of obesity therapies will increase over the next 10 years, boosting the market size, Wong says. Still, there is a lack of reimbursement for obesity drugs in the US and public health systems throughout the rest of the world, which could hinder any further market growth. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Agency for Medical Innovation - Allergan - Apollo Endosurgery - Arena Pharmaceuticals and Eisai - Aspire Bariatrics - Bariatric Solutions - Baronova - BaroSense - BFKW - C.R. Bard - Cousin Biotech - Endalis Laboratory - EndoGastric Solutions - EndoSphere - EnteroMedics - Ethicon Endo-Surgery - GI Dynamics - Helioscopie - IntraPace - Medical Innovation Development - MetaCure - Novo Nordisk - Obalon Therapeutics - Orexigen Therapeutics - ReShape Medical - Roche Holdings - Shionogi - Spatz Medical - Takeda Pharmaceutical Company - ValenTx For more information visit http://www.researchandmarkets.com/research/l5...harmapoint
Orexigen Therapeutics Shares Up 14.4% Since SmarTrend's Buy Recommendation (OREX)
Comtex SmarTrend(R) - Wed Feb 26, 9:59AM CST
SmarTrend identified an Uptrend for Orexigen Therapeutics (NASDAQ:OREX) on January 10th, 2014 at $6.30. In approximately 2 months, Orexigen Therapeutics has returned 14.44% as of today's recent price of $7.21.
Arena Pharmaceuticals, Inc. Earnings: What to Expect Thursday
Dan Caplinger, The Motley Fool - Motley Fool - Tue Feb 25, 11:01PM CST
Arena Pharmaceuticals will release its quarterly report on Thursday, and investors are more nervous than ever about the prospects for the maker of obesity drug Belviq. With rival VIVUS having reported another round of disappointing sales of its...
Why SINA, VIVUS, and Tenet Healthcare Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Tue Feb 25, 7:30PM CST
Stocks finished narrowly lower on Tuesday, as investors seemed content with the impressive gains they've scored so far this month after a terrible January. Yet even though broad market benchmarks fell only a fraction of a percent, much larger losses...
Another Big Failure for VIVUS, Inc.
David Williamson, The Motley Fool - Motley Fool - Tue Feb 25, 4:02PM CST
Vivus Pharmaceuticals is having an absolutely awful day, with the stock down more than 13% after the company reported its Q4 results. The launch of its first-in-class obesity drug Qsymia was very highly anticipated among investors with the market...
Why VIVUS Inc. Shares Slimmed Down
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 25, 11:58AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of VIVUS , a biopharmaceutical company...
Moving Average Crossover: Great News Orexigen Therapeutics (OREX)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 9:01AM CST
Moving Average Crossover: Great News Orexigen Therapeutics (OREX)?
Why VIVUS Inc. Is Falling Today
George Budwell, The Motley Fool - Motley Fool - Tue Feb 25, 8:33AM CST
VIVUS reported earnings after the bell yesterday and its shares have been on a roller coaster ride ever since. Immediately following the release, shares rose over 4%, but have now fallen close to 13% in premarket trading this morning. ...
Orexigen Provides Update on Its NB32 European Marketing Authorization Application
PR Newswire - Tue Feb 25, 7:00AM CST
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that the Company received the Day 120 List of Questions (LoQs) regarding its NB32 Marketing Authorization Application (MAA) from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP). The EMA reviewers' questions are consistent with issues raised by the United States Food and Drug Administration during the course of NB32 development and the initial review of the New Drug Application, such as manufacturing and quality, non-clinical studies, dosing regimen, and, most significantly, cardiovascular safety. The NB32 MAA is being reviewed by EMA regulators for the first time, and the LoQs represent the first formal interaction with the regulators since the MAA was filed in October. Orexigen is confident that it can successfully address all of the questions posed.
